Envestnet Asset Management
TVRD

Envestnet Asset Management’s Tvardi Therapeutics TVRD Stock Holding History

Envestnet Asset Management’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-994
Closed -$32.6K – 4311
2024
Q1 		$32.6K Buy
+994
New +$25.8K ﹤0.01% 4127
2022
Q4 		– Sell
-317
Closed -$107K – 4091
2022
Q3 		$107K Sell
317
-150
-32% -$54.3K ﹤0.01% 3725
2022
Q2 		$153K Sell
467
-118
-20% -$41.4K ﹤0.01% 3686
2022
Q1 		$256K Buy
+585
New +$240K ﹤0.01% 3541

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Envestnet Asset Management's TVRD Position: Q2 2024 in Review

Envestnet Asset Management sold out of Tvardi Therapeutics (TVRD) in Q2 2024, closing a stake of 994 shares — an estimated $32.6K sold.

Envestnet Asset Management first reported a position in TVRD in Q1 2022 and held it in 4 quarters. The position peaked at $256K in Q1 2022. 79 funds tracked by Wall St. Rank hold TVRD as of Q2 2024.

  • Envestnet Asset Management reported no remaining Tvardi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Envestnet Asset Management sold 994 Tvardi Therapeutics shares in Q2 2024, an estimated $32.6K.
  • Envestnet Asset Management first reported a position in Tvardi Therapeutics in Q1 2022 and held it in 4 quarters.
  • Envestnet Asset Management's Tvardi Therapeutics position peaked at $256K in Q1 2022.
  • 79 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2024.

Based on Envestnet Asset Management's 13F filing for Q2 2024, filed 8 Aug 2024.